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Abstract 
Huntington disease (HD) can be seen as a model neurodegenerative disorder, in that it is 
caused by a single genetic mutation and is amenable to predictive genetic testing, and 
estimation of years to predicted onset, enabling the entire range of disease natural history to be 
studied. Structural neuroimaging biomarkers show that progressive regional brain atrophy 
begins many years before the emergence of diagnosable signs and symptoms of HD, and 
continues steadily during the symptomatic or ‘manifest’ period.  The continued development of 
functional, neurochemical and other biomarkers are now in development, raises hopes that 
these biomarkers may be useful for future trials of disease-modifying therapeutics--ie to delay 
the onset and slow the progression of HD. Such advances could herald a new era of 
personalized preventive therapeutics in HD. In this Review, we describe the natural history of 
HD, including the timing of emergence of motor, cognitive and emotional impairments, and the 
techniques that are used to assess these features. Building on this information, we also review 
recent progress in the development of biomarkers for HD, and the potential future roles of these 
biomarkers in clinical trials.  
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Key points 
 
 There are currently no disease-modifying treatments available for 
Huntington’s disease (HD) but clinical trials of potential compounds are 
imminent; identifying suitable biomarkers to assess therapeutic efficacy is 
consequently a main priority in HD research.  
 Quantifiable measures of patient function including motor and cognitive 
assessments have shown disease-related change in early HD but still lack 
sensitivity in premanifest cohorts.  Nevertheless, functional readouts are 
essential to demonstrate clinical benefit.       
 Structural imaging measures such as striatal atrophy show the largest 
effect sizes both cross-sectionally and longitudinally, and have the 
potential to track disease progression even in the premanifest period.   
 Functional MRI and MRS are also sensitive for detecting change, but have 
not yet been well-validated longitudinally.   
 PET imaging is quantitative and shows sensitivity to early premanifest 
disease, and may be useful longitudinally, though has the disadvantage of 
being expensive and complex.     
 Biochemical assays of relevant molecules are highly desirable since they 
may provide more direct reflection of disease mechanisms. Such measures 
have not been fully validated and future work will focus on their 
development, in particular assessment of mutant huntingtin itself.  
 A range of biomarkers with potential for use in clinical trials have been 
identified, but selection of the most appropriate measure will depend on 
the study cohort, time interval and the expected mechanism of therapeutic 
intervention.  
 HD may provide a model for studying biomarkers and experimental 
therapeutics relevant to other neurodegenerative diseases 
 
 
 
Introduction 
  
Huntington disease (HD) is caused by a CAG repeat expansion in the huntingtin (HTT) gene on 
chromosome 4, which codes for polyglutamine in the huntingtin protein.  Above a threshold of 
about 35 or more repeats, the age of onset is inversely proportional to the length of the 
expansion with variable age-dependent penetrance between 36 and 39 repeats, but full 
penetrance at 40 or greater CAG repeats. .  In addition, it has been suggested that there may 
be subtle abnormalities, possibly constituting an endophenotype, in the rare individuals who 
have repeat lengths in the 27-35 range (Squitieri and Jankovic 2012; Seong  et al 2005)).  HD 
classically manifests with a triad of signs and symptoms, including motor, cognitive and 
behavioural features.1,2 According to the current criteria, onset is defined as the point when a 
person who carries a CAG-expanded HTT allele develops “the unequivocal presence of an 
otherwise unexplained extrapyramidal movement disorder (for example, chorea, dystonia, 
bradykinesia, rigidity).”3,4 We add the presence of cognitive disorder as characteristic of HD, and 
an important contributor to disability. Emotional disorders and personality changes are common 
and may be a cause of distress, but are not universal, and seem not to progress steadily as do 
the motor and cognitive changes. 
How we define terms such as ‘disease’ and ‘disability’, and how we draw the line 
between ‘normal’ and ‘abnormal’, has long been a point of discussion not only in HD research, 
but also in the wider fields of medicine, public health, and disability studies. These distinctions 
have cultural and social as well as biological dimensions. The slow progression of changes 
initiated by the CAG-expanded HTT allele can be usefully considered in the context of recent 
disability theory. From this perspective, what is currently considered as ‘premanifest’ and ‘early-
stage HD’ is a period of increasing impairments (biologically-based limitations or losses) with 
environmentally relative disabilities (that is, disadvantage related to the social environment; for 
example, the inability to drive in a suburban or rural environment, where driving is important for 
full independence. The prospect of clinical trials for HD increases the need for useful biological 
benchmarks. Ironically, the closer attention to measurement in the premanifest period also risks 
enlarging the category of the so-called ‘pathological’ through more-refined ways of measuring 
difference, thereby potentially increasing stigmatization and the psychological burden for people 
at risk. On the other hand, a diagnosis of disease may have some social benefits, conferring 
legitimacy on symptoms, and opening access to services. 
 In this Review, we begin by outlining the natural history of HD, mapping the emergence 
of motor, cognitive and emotional disorders. We review the aspects of the disease biology of HD 
relevant to biomarker development.  We then go on to an integrative discussion of the current 
status of biomarker validation in HD, and the prospects for incorporating these biomarkers into 
future clinical trials. Biomarkers (Box 1) for HD (Weir et al 2011) could aid both cross-sectional 
assessments and longitudinal monitoring in clinical trials.  Cross-sectionally, biomarkers may 
assist in participant selection and stratification, and statistical covariance for higher power to 
detect treatment effects. For biomarkers to be useful longitudinally, they must show consistent 
changes with progression of the disorder, and should predict some aspects of clinical 
progression. They must also be responsive to therapeutics. Ideally, a biomarker will be close 
enough to the disease process and sufficiently predictive of future progression that it can be 
used as a ‘surrogate marker’ (Box 1).  
 
The course of HD can be divided into ‘premanifest’ and ‘manifest’ periods (Figure 1). 
The premanifest period can be further subdivided into a period when individuals are not 
distinguishable clinically from controls (‘presymptomatic’), usually up to 10–15 years before 
onset. Patients may then enter the ‘prodromal’ period, which is characterized by subtle motor, 
cognitive and behavioural changes. Once motor and cognitive signs and symptoms begin, they 
progress inexorably over the course of the illness, which—with the exception of late-onset 
cases, who may die of other causes—is uniformly fatal.  
  
The Unified HD Rating Scale (UHDRS) is currently the most commonly used clinical and 
research tool for the assessment of HD. This scale includes motor, cognitive, behavioural, 
emotional and functional components. The clinical assessment of premanifest individuals 
currently includes a ‘diagnostic confidence score’ subscale of the UHDRS, which scores the 
motor examination according to the clinician’s belief that the motor signs represent HD, from 0 
(no motor abnormalities suggestive of HD) to 4 (motor abnormalities ≥99% likely to be due to 
HD).3,7,8 A patient who receives a score of 4 on this scale for the first time, when assessed by an 
expert rater, is said to have experienced ‘motor onset’. The advantage of this model is that, 
amid the considerable clinical phenotypic heterogeneity of the disease, motor onset emerges as 
one of the more robust and consistently agreed disease features.3 However, the diagnostic 
confidence score involves subjective assessment of ambiguous probabilities, and the concept of 
motor onset, or ‘phenoconversion’, especially if interpreted simplistically, may suggest a false 
dichotomy between sick and well, obscuring the fact that disease onset is really a process that 
occurs gradually over years or even decades. 
The manifest HD period is sometimes divided into five stages.7,8 However, these stages 
are purely descriptive characterizations based on continuously changing functional capacity 
rather than on biology. This situation contrasts with many other diseases, such as cancer, in 
which staging relates to biological events with specific implications for prognosis and treatment. 
For instance, staging systems for breast or colon cancer are based on events such as 
conversion of cells to unchecked growth, penetration of the lamina propria, dissemination to 
lymph nodes, and metastasis to distant locations. These events critically influence prognosis, 
choice of treatments, and response to those treatments. Without such biological events to 
determine staging in HD, we think it simpler to divide HD into three broad phases: ‘early’ 
(patients are generally still active in most areas of functioning, and are often still working or 
driving), ‘moderate’ (patients become unable to perform complex functions such as work, driving 
or shopping independently, but still take care of activities of daily living [ADLs] and simple 
household tasks), and ‘late’ stages (patients can no longer take care of ADLs without help). 
The systematic study of HD, leading to the identification of the HTT gene, began with the 
seminal and continuing study of the condition in a very large pedigree in Venezuela.15,16 
Subsequently, HD research has benefited from several longitudinal single-centre and 
multicentre studies. PREDICT-HD9 is a large multicentre study with a total of about 800 
premanifest HD cases and 200 control individuals, studied by use of clinical, neuropsychological 
and imaging measures for up to 10 years. TRACK-HD has studied 360 individuals (120 
premanifest HD cases stratified by time to predicted onset, 120 early-stage patients, and 120 
matched controls), with extensive annual assessments involving imaging and clinical 
measures.10–13 Figure 2 shows the 36-month longitudinal data from TRACK-HD. REGISTRY is 
the largest multicentre study to date, with over 10,000 participants from 16 countries.14 A single-
site study at Johns Hopkins has followed HD families clinically for over 30 years, with some 
neuropsychology and imaging, and in many cases has followed individuals through the late 
stages of the disease to autopsy and neuropathological diagnosis (Rosenblatt et al 2004).   
  
The CAP score   
The age of clinical onset in HD is highly variable (with a mean of ~45 years), but is strongly 
influenced by the length of the CAG trinucleotide expansion within the HTT gene.17 The 
influence of CAG repeat length on rate of disease progression is less strong but still 
significant.18 To estimate the progression of HD pathology as a function of CAG repeat length 
and time of exposure to the effects of the expansion, a variable of the form AGE × (CAG – L)—
where AGE is the current age of the individual, CAG is the repeat length, and L is a constant—
was first proposed by Penney et al. in 1997.19 The authors showed that an index of this form 
was a good predictor of striatal pathology in the brains of HD patients at autopsy.  
  
 The terms ‘disease burden’ and ‘genetic burden’ have been used to designate the 
Penney et al. version of this statistic, but we prefer the more neutral ‘CAG–age product’ (CAP). 
A form of a CAP score was used in the TRACK-HD study as a premanifest HD entry criterion,10 
and the PREDICT-HD study uses a CAP score at entry to the study to distinguish among 
patients predicted to be close to, middle, or far from predicted onset at study entry.20 For the 
purposes of this Review, we use a standardized CAP score derived from convergent evidence 
from several large HD data sources (see Box 2 for derivation of this score). This score provides 
an index of the length and severity of the individual’s exposure to the effects of the mutant HTT 
gene, which is useful for conveying longitudinal data from cohorts of patients with a range of 
ages and CAG repeat lengths. 
 In Figure 3, we plot clinical measures from TRACK-HD against the CAP score, and in 
Figure 4 we plot a variety of clinical measures from the combined data sets of COHORT and 
REGISTRY against the CAP score.14,21,22  One question raised by these data is whether there is 
an acceleration of changes in clinical measures around the time of onset of manifest HD. This 
issue will need more study in additional data sets, or in current data sets with more-
sophisticated models. 
 
Motor disorder 
The motor disorder of HD can be divided into two broad components. The first component 
consists of involuntary movements, especially chorea. Chorea is most prominent with adult-
onset or late-onset HD, begins early in the course of the disease, and gives HD its characteristic 
clinical appearance. The second component involves impairment of voluntary movements, and 
includes incoordination, bradykinesia and rigidity. This component tends to predominate in 
earlier-onset HD (including juvenile HD, which is quite rare) and in the late stages of the more 
common adult-onset HD, progresses more steadily than chorea,23 and also correlates with 
functional disability better than does chorea.18  
 Clinical assessment of the motor deficits in HD often uses the Unified Huntington's 
Disease Rating Scale Total Motor Score (UHDRS-TMS).3 The Hopkins study for many years 
used the Quantitative Neurological Examination (QNE),24 a precursor to the UHDRS with 
different items but similar scoring. The UHDRS motor scale, like the QNE, has ratings for items 
including eye movements, speech, chorea, dystonia, rapid alternating movements, 
bradykinesia, and gait. Scores on the UHDRS motor scale range from 0–124. Subtle motor 
changes begin years prior to diagnosable HD, and by the time that motor scores reach 15–20, 
clinicians usually feel confident enough to assign a diagnostic confidence score of 4, indicating 
manifest HD. 
Several measures have been developed to further quantify motor dysfunction. Simple 
and easily quantifiable measures of motor function can be derived from tapping on a computer 
keyboard;9 speed and consistency of tapping represent a simple means to quantify motor 
performance. More-complex and quantified metronome-paced tapping tests can improve 
quantification.25 Specialized force-transducer-based measures can also be used to quantify 
motor performance, as in the quantitative motor (Q-Motor) battery used in TRACK-HD.12 Finger 
tapping (digitomotography) was used to assess disease progression in all subgroups of the 
TRACK-HD study across 2 and 3 years.12,26 Tongue force variability and grip force variability 
have also been used to quantify motor features in manifest26–28 and premanifest26  HD.29  Q-
Motor assessments can potentially be standardized across centres; they can be administered 
by technical assistants and may be applied repeatedly within a study, although they require 
specialized equipment, and have not been compared directly with simpler keyboard-based 
measures. 
 
Cognitive disorder    
  
Cognitive impairments emerge 9–15 years before diagnosis of HD,31 and progression of 
cognitive decline is gradual. In early manifest HD, significant rates of decline are detectable over 
12 months in a subset of cognitive tests,11 and more broadly after 24 months,32 whereas in 
premanifest HD, significant rates of cognitive decline are detectable across 36 months, and only 
in those individuals estimated to be about 10 years or less from diagnosis.13 Although cognitive 
decline in HD always occurs, individuals vary with respect to how the cognitive disorder 
manifests. Some evidence indicates that various aspects of cognition decline at different points 
in the disease course,33 although this variability might be partly explained by the fact that 
measures of some aspects of cognition, such as psychomotor slowing, are more sensitive than 
are other aspects of cognition, such as executive function. Several of the frequently used 
‘cognitive’ tests (see below) have a substantial motor component. 
The profile of cognitive decline in HD bears similarities to other disorders associated with 
striatal–subcortical brain pathology (for example, vascular dementia and Parkinson disease), 
but it differs from Alzheimer disease.34 Cognitive deficits in HD include cognitive slowing, as well 
as decreased attention, mental flexibility, planning, visuospatial functions and emotion 
recognition.31,32,34 Learning and retrieval of new information are impaired but, in contrast to 
Alzheimer disease, rapid forgetting is not as pronounced,35 and language is relatively preserved. 
Many cognitive deficits in HD occur at the intersection between cognitive and psychiatric realms 
of function, including problems with initiation, lack of awareness of deficits, and disinhibition.36 
Thus, a typical picture of HD that emerges over time is that of social disengagement, low 
conversational participation, and slowed mentation, sometimes overlaid with lack of awareness 
of deficits and impulsivity. 
 The number of cross-sectional HD studies far outstrips the number of longitudinal 
studies, making rates of progression in different aspects of cognition or at different points in 
disease progression difficult to ascertain.  However, in the TRACK-HD study, ten of 12 cognitive 
outcomes showed evidence of deterioration in early HD (Tabrizi, Scahill et al. 2011; Tabrizi, 
Reilmann et al. 2012; Tabrizi, Scahill et al. 2013). The greatest sensitivity to progression was in 
the Symbol Digit Modalities Test (visual attention and psychomotor speed), the Circle Tracing 
Test (visuomotor and spatial integration and transformation), and the Stroop Word Reading Test 
(psychomotor speed within the spoken context), with effect sizes (compared with controls) of up 
to 1.00 (95% CI 0.70–1.30). By contrast, in relatively late premanifest HD, a sample of 117 
participants showed little evidence of detectable deterioration across 24 months. Many of the 
tests with the largest effect sizes cross-sectionally, as well as great change longitudinally, have 
a substantial motor or psychomotor component, emphasizing the close relationship between 
motor and cognitive features of HD, both of which are presumably linked to cortical–basal 
ganglial circuits. 
 
Emotional disorders 
The emotional features of HD are more variable than are the motor or cognitive features. 
Depression is common, with depressive symptoms reported in over half of patients.37 Major 
depression in HD resembles depression in individuals without HD, and is treated similarly.38 
Irritability is frequently present in HD, and might be an early symptom. Apathy is a characteristic 
and disabling feature of the disorder, is present in most individuals at least by later stages of the 
disease, and tends to worsen with time.37 Strikingly, recent data from TRACK-HD indicate that a 
significant increase in apathy can be detected even in premanifest individuals over 36 months—
this was the most striking single psychiatric indicator that demonstrated clear longitudinal 
progression.13 In early HD, baseline apathy scores were a significant baseline predictor of 
functional decline, and neuropsychiatric symptoms associated with frontal lobe function, such as 
affect, irritability and apathy, were significantly associated with functional decline in early HD.13 
 
Biomarkers for HD 
  
Relevant biology of HD  
Many pathogenic mechanisms have been hypothesized for HD, but some are likely to be more 
relevant than others for biomarker development (Figure 5). HD is potentially a good model for 
development of biomarkers of direct relevance to pathogenesis, since it is caused by a single 
gene mutation and has an increasingly well-understood pathogenic pathway. A great need 
exists for target engagement biomarkers; however, they tend to be treatment-specific, and will 
not be the focus of this Review. Most attention in the past has focused on the CNS, but it is 
becoming clear that some peripheral tissues are also affected in HD. Consequently, peripheral 
biomarkers, such as inflammation, hold somepromise.39, 119, 120, 131 
 Some of the earliest steps in the pathogenic cascade of HD include misfolding of 
huntingtin to a β-sheet structure,40 and post-translational alterations, such as cleavage or 
altered phosphorylation. Specific antibodies could be developed to monitor these events. The 
mutant huntingtin protein has many effects in cells, including abnormalities in cellular 
proteostasis mechanisms, for which reporters might be available.41 The mutant protein can 
enter the nucleus and alter gene transcription,42 the consequences of which could, conceivably, 
be measured. Mutant huntingtin can also affect cellular metabolism; in particular, mitochondrial 
function, which may lead to the production of abnormal metabolites and markers of oxidative 
stress.43 
Age of onset and rate of progression of HD are both likely to be influenced by 
environmental and genetic modifiers.16,44 CAG repeat length explains about  50-to 70% of the 
variance of age of motor onset, and the residual variance has a heritability of  > .50 (Gusella 
and MacDonald, 2006).   
Thus far the attempts to find genetic factors other than the CAG repeat length that 
modify age of onset by examining the HD locus (Lee et al, 2012) or specific candidate genes 
(Ramos et al, 2012) or by genome wide linkage analyses (Gayan et al, 2008), have yielded 
negative results, or intriguing but inconsistent leads.  Novel and robust genetic modifiers will, 
hopefully, emerge from new approaches, such as using GWAS for large series of cases or 
applying whole genome sequencing to small pedigrees with at least two affected individuals in 
different generations (Roach et al, 2010).  Additional modifiers may emerge from careful 
examination of rare cases of HD that appear to develop with repeat lengths below the canonical 
threshold of 36 CAG triplets (Squiteri and Jankovic 2012).  Finding genetic modifiers may 
provide leads to biomarkers.     
 
Neuronal death is the hallmark of HD, but neuronal dysfunction manifesting in clinical 
features probably occurs prior to actual cell death.  Chorea has been suggested to reflect 
neuronal dysfunction,45 while motor impairment (bradykinesia/fine motor dysfunction) seems to 
be best correlated with neuronal cell death.  This idea would be consistent with the observation 
that chorea tends to predominate early in the disease course while motor impairment 
supervenes later in the course. Supporting this hypothesis, motor impairment—but not chorea—
has been found to correlate with both the Vonsattel score (a measure of neuropathological 
severity) and loss of neurons as determined by stereology in postmortem striatum.46 
Evidence for neuronal dysfunction, including synaptic dysfunction, is plentiful in animal 
models of HD,47 and evidence that such dysfunction can be reversible comes from both 
conditional knockout models48 and nucleotide-based gene silencing in mice.49,50 Reversal of 
dysfunction seems possible even to the extent that reversal of both histopathological and 
neurological abnormalities is seen when production of mutant huntingtin is reduced. Thus, 
biomarkers relating to both neuronal dysfunction and neuronal cell death are likely to be 
important. 
Another important issue relates to cell-autonomous versus cell-interaction mechanisms 
in HD pathogenesis. Mutant huntingtin is likely to have cell-autonomous toxic effects, but there 
may also be elements of cell interaction, which could be mediated in several different ways, 
  
including excitotoxicity, spread of abnormal mutant huntingtin from cell to cell in a prion-like 
fashion,51 and loss of trophic support from brain-derived neurotrophic factor or other trophic 
molecules. Whatever the biological mechanism, the implication is that localized changes might 
be propagated in a topographic manner (Figure 6), which could have profound implications for 
the design of therapeutic interventions, especially those involving localized huntingtin lowering. 
 
MRI methods 
Macrostructural brain imaging 
To date, structural imaging has been the source of the most robust biomarkers for HD 
(Georgiou-Karistianis et al 2013). Structural MRI methodologies have demonstrated strong 
cross-sectional and longitudinal changes in volumes of the striatum, in both premanifest and 
manifest HD.10,52–60 Large longitudinal studies (PREDICT-HD and TRACK-HD) have shown 
significantly faster rates of decline in striatal volume in premanifest and manifest HD individuals, 
compared with age-matched controls, even in those individuals who are >15 years from 
estimated onset of diagnosable signs.61,62 Studies using raw volumes to calculate longitudinal 
change suggest that once atrophy begins, the rate remains fairly constant, and rate is 
significantly faster in those with higher CAG repeat lengths.52,61,62 
 Other regions, such as the globus pallidus, thalamus and hippocampus, also undergo 
atrophy, though less attention has been paid to these structures. Cross-sectional and 
longitudinal studies indicate that the magnitude of volume reduction is smaller in these regions 
than in the striatum  61,63, 132 
 
Cortical grey matter atrophy occurs later than striatal atrophy in premanifest HD,61 and is less 
dramatic than striatal atrophy in both manifest and premanifest stages of disease.10,64 Results 
from cross-sectional studies differ regarding specific areas of cortical involvement (Rosas et al 
2008; Aylward et al 2011; Nopoulos et al 2011).  Longitudinal data from PREDICT-HD suggest 
that rates of change in cortical volume do not distinguish individuals with premanifest HD from 
controls.61 Longitudinal studies in manifest HD indicate significant change over 1–2-year 
periods,62 and faster rates of change as compared with controls.65 
 White matter volume is significantly reduced long before motor onset in HD,10,61,63,66–68 
and atrophy continues into the manifest period.10,64,69 Longitudinal studies show significant 
atrophy over 1–2-year periods in premanifest HD61,62 and early manifest HD.11,65 Using 
Statistical Parametric Mapping methodology, the TRACK-HD group11 found that the most 
prominent changes in white matter occurred around the striatum and within the corpus callosum 
and posterior white matter tracts. Longitudinal atrophy of the corpus callosum in both 
premanifest and early HD cohorts has been confirmed by a recent volumetric study (Crawford et 
al in press). Aylward et al., using lobular regions of white matter, found the greatest volumetric 
change to reside in the frontal lobe.61, 133 
 Changes in subcortical structures can also be detected using shape analysis (van den 
Bogard et al 2011; Younes et al 2012).  This may be more sensitive than volumetric analysis 
and gives additional information about which subportions of brain regions may be affected.   
 
Microstructural brain imaging 
 Diffusion tensor imaging (DTI) has revealed abnormalities in neuronal fibre orientation 
and integrity in both white matter and subcortical grey matter structures in both premanifest70–73 
and manifest58,60,71,74–79 HD. In white matter, the greatest differences are generally found in the 
corpus callosum. As yet it is not established which processes contribute to volumetric loss in 
this structure, for example a reduction in neuronal density and/or demyelination, but recent 
advances in diffusion imaging are likely to further elucidate relevant mechanisms.  Abnormalities 
in the cortico-cortico fibers in corpus callosum could result in cortical “disconnection” effects 
(Rosas et al 2009).   
  
Several studies have shown increased fractional anisotropy (or reduced diffusivity) in the 
basal ganglia—in particular, the putamen—in manifest and premanifest HD,58,60,71,72,74,77,79 with 
less-consistent findings in the globus pallidus and caudate before diagnosis. The interpretation 
of increased fractional anisotropy is uncertain. This parameter has been proposed to reflect the 
microstructure and organization of fibre tracts, but another possibility is that as neurons die, 
white matter tracts passing through are proportionately over-represented, resulting in increased 
fractional anisotropy. Other measures from DTI, including mean diffusivity, and radial and axial 
diffusivity, have also been found to be abnormal in HD.60,76 
 
Functional and chemical MRI 
Imaging methods that probe functional and metabolic disturbances might be especially 
useful early in the HD course, perhaps even before structural changes begin, and could be 
more responsive to therapeutic interventions compared with structural imaging measures  
 Functional MRI (fMRI) incorporating blood oxygen level-dependent (BOLD) contrast can 
provide a reflection of neuronal activity, and might be capable of identifying changes in 
premanifest HD even before structural brain damage.81–85 Functional changes may include 
regional overactivation and underactivation, which could be interpreted as signs of dysfunction, 
compensatory overactivity, or both. Consequently, interpretation of fMRI data can be complex It 
is not clear whether increases or decreases would be expected in response to therapeutic 
intervention. Functional connectivity can also be measured using fMRI  by synchrony of the 
BOLD signal in spatially remote brain regions. In premanifest HD, functional connectivity has 
been reported to be abnormal in the motor system86,87 (Wolf et al 2012)and in systems related to 
cognitive processing.83,84,88–91 (Wolf et al 2008).  An advantage of using functional connectivity is 
that it can be measured while the patient is at rest, and thus interpretation does not require 
consideration of differences in task performance.  Nevertheless, further work validating the test-
retest reliability of fMRI data, the consistency across multiple sites, and the presence of 
progressive longitudinal changes is required before this technique is adopted for clinical trials. 
 Another promising magnetic resonance-based approach to identify early brain changes 
in HD is magnetic resonance spectroscopy (MRS), which has been used to identify alterations 
affecting N-acetylaspartate (NAA), glutamate and glutamine.92–94 Levels of myoinositol, a marker 
of astrocytosis, have also recently been found to be elevated in the putamen of patients with 
early HD, correlating with motor dysfunction.94 Recent MRS studies using high-field-strength 
MRI have confirmed the results of earlier studies, especially the alterations in NAA and 
glutamate levels.95 MRS at high field strength, with its increased signal-to-noise ratio and 
spectral resolution, can be used for investigation of additional metabolites, such as lactate, 
gluthatione and γ-aminobutyric acid, and might increase power for identification of physiological 
measures associated with early brain change in HD.95 Potential MRS markers of interest could 
subsequently may be assessed at the more-routine field strengths available with clinical MRI 
scanners, perhaps using spectral editing methods.   
 MRI can also be used to assay brain iron and other transition metals.  Brain iron has 
been reported to be altered in HD (Rosas et al 2012).   
 
Clinical–imaging correlates 
Striatal volumes correlate with CAP scores and estimated time to disease onset in premanifest 
HD,9,57,63,96,97 as do white matter measures.63,67,98 Measures of motor dysfunction also strongly 
correlate with the volume of the striatum56,99,100 and white matter .71,100,101 Using 
digitomotography, the TRACK-HD group25 found significant correlations between motor scores 
and volumes of the caudate, putamen and grey matter in the right superior temporal and left 
precentral gyrus, as well as cortical thickness in the occipital and parietal lobes and primary 
motor cortex. 
  
 Measures of cognitive function show a strong correlation with imaging 
variables.55,59,63,69,100,103 The association of corpus callosal atrophy and impairment on a 
visuomotor integration task in early HD suggests that a reduction in inter-hemispheric 
communication may have a direct impact on HD symptomatology.133 By contrast, little or no 
correlation is observed between structural imaging measures and psychiatric 
symptoms.63,75,100,103 Measures of functional capacity correlate with total grey and white matter 
volumes64,67,104 and striatal volumes in manifest HD.99 Patterns of cortical thinning have been 
linked to other specific phenotypes that represent heterogeneity in clinical presentation and 
rates of progression.105–107 
 White matter DTI measures correlate with estimated years to HD onset,73 cognitive 
measures,71,75,78,79 motor measures,75,79 and apathy.79 MRS and fMRI measures have been 
studied less extensively, but correlations with clinical variables have been reported in very small 
cross-sectional studies.91,95 One fMRI study reported reduced activation in the dorsolateral 
prefrontal cortex associated with increasing working memory load in premanifest HD (Wolf et al 
2007 PMID 17855375; Wolf et al 2008) and in another study,  premanifest subjects who 
performed at a similar level to controls on a motor task employed a compensatory network in 
the supplementary motor area (Kloppel et al 2009 PMID 19369489). However, there are few 
longitudinal fMRI studies and a recent study by Wolf et al failed to show change in activation 
over a two year period (Wolf et al, 2012 Exp Neurol).   
   
PET methods 
Initial 18F-fluorodeoxyglucose (FDG)-PET studies in patients with HD showed glucose 
hypometabolism in the striatum, with a suggestion of possible hypermetabolism preceding the 
decrease.109 A recent longitudinal study reported decline in glucose metabolism in rapidly 
progressing early HD patients .134 An alternative approach is to delineate a network of regions 
with altered metabolism.110,111 These findings show that FDG-PET, in combination with state-of-
the-art network analysis tools, may identify specific patterns of abnormal brain function in 
prodromal stages of HD. Patterns of metabolic alterations in preclinical HD might be used as 
measures for quantifying the rate of disease progression during the earliest disease phases. 
FDG-PET analyses might also provide suggestions of possible spread of HD-related pathology. 
A recent study suggested that alterations in metabolic network measures may provide useful 
markers for clinical trials135, although interpretation of network pattern changes and their impact 
on clinical performance may be complex. 
 
 
Prediction of key clinical changes 
 
For imaging measures to be candidate surrogate measures, they should ideally not only 
correlate with clinical measures, but also be able to predict these measures. One study has 
shown that striatal volumes can predict motor onset and adds predictive power beyond age and 
CAG repeat length alone.108  Another has study has shown that PET 2DG hypometabolism is 
also a predictor, though has not determined whether it adds additional predictive power beyond 
striatal volumes (Ciarmiello et al 2012)..   
 
Other biomarkers 
Biochemical measures of pathogenically relevant processes in accessible biofluids would be 
highly desirable as biomarkers for HD. Despite the ubiquitous expression of mutant huntingtin, 
the development of biochemical biofluid biomarkers for HD has proved challenging.112 
Hypothesis-driven and ‘omics’ discovery approaches have yielded a multitude of candidate 
biomarkers,113,114 but none can be said to have been ‘validated’.112 
  
 An example of the difficulties is 8-hydroxydeoxyguanosine (8OHdG), a product of 
oxidative DNA damage, which was reported to be elevated in plasma from patients with HD, 
and to be responsive to treatment with the antioxidant creatine.115 However, in a larger patient 
cohort in whom 8OHdG was quantified by the original laboratory, only a subtle alteration was 
found in patients with HD.116 In a separate study (PREQUEL), no relationship was observed 
between CAP scores or projected years to onset and 8OHdG levels, and no change in levels of 
this compound were seen after  treatment with coenzyme Q10 (CoQ10), another antioxidant. 
Furthermore, a rigorous, two-laboratory, blinded analysis recently reported no disease-related 
alterations in 8OHdG levels at any stage of HD, or any significant change with longitudinal 
progression.117 The authors concluded that 8OHdG is not a useful biomarker for HD onset or 
progression. This work emphasizes the importance of independent replication of results, blinded 
sample analysis, use of multiple analytical methods, and rigorous biosample quality control for 
future HD biomarker studies 
 Future work in biofluid biomarkers is likely to focus on pathogenically relevant molecules 
in the cerebrospinal fluid (CSF). Unbiased omics discovery approaches in CSF have not yet 
identified good candidate biomarkers in HD.118 Hypothesis-driven studies will focus on functional 
correlates and neurobiological underpinnings of detectable changes already reported, such as 
immune activation,39,119,120 transcriptional dysregulation121 and cholesterol biosynthesis.122 
Another possibility would be to attempt to track striatal degeneration using CSF markers such 
as DARPP32 or TCIP2, which would be predicted to be released into the CSF by dying medium 
spiny neurons. 
 Direct quantification of the mutant huntingtin protein itself shows promise as a 
pathogenically relevant marker.123,124 Mutant Htt levels are seen to rise with disease progression 
due to the accumulation of N-terminal fragments, while mHTT concentration is correlated with 
both CAP score and brain atrophy rate, indicating potential functional relevance.123, 124, 125 If work 
that is currently underway to further improve these assays is successful, accurate quantification 
of mutant huntingtin in CSF might be useful, analogous to the current use of amyloid-β peptides 
and tau isoforms in Alzheimer disease.126 A more valuable approach, however, might be to 
identify specific post-translational modifications or abnormal conformations of huntingtin that 
correlate with disease pathogenesis. 
 
Conclusions and future prospects   
Current clinical trials in manifest HD have required large numbers of participants (for example, 
600 subjects over 5 years for the 2CARE study of CoQ10). Clinical trials in premanifest HD with 
clinical outcomes such as motor onset could require even larger numbers of participants, if 
individuals are not selected on the basis of age and CAG repeat length.Use of structural 
imaging biomarkers as outcome measures in clinical trials could potentially decrease the 
number of participants needed for efficacy trials of neuroprotective agents in HD, as the effect 
sizes for these structural imaging measures are so large relative to clinical measures12, 13 that 
sample size calculations for effectively powered studies result in smaller numbers of participants 
needed. 
Until biomarkers can be established as surrogate markers, phase III clinical trials must 
have relevant clinical end points. Nevertheless, biomarkers could be extremely useful for phase 
II clinical trials in which the goal is to assure safety and gather initial evidence  that an agent has 
neuroprotective properties and, thus, merits being taken to larger phase III trials with definitive 
clinical end points. 
HD can provide a model for other neurodegenerative disorders, since it is caused by a 
single mutated gene and has a characteristic and well-known neuropathology and allows the 
study of the premanifest phase of neurodegeneration in humans, when therapeutics are most 
likely to be efficacious at slowing or reversing the disease.  The relationship between CAG 
repeat length and age of onset makes it uniquely possible in studying HD to predict the age of 
  
onset in premanifest cases--in a fashion not possible even for the rare single gene causes of 
Alzheimer’s disease or Parkinson’s disease.  Furthermore, since HD is also a protein misfolding 
disorder--like Parkinson’s disease and Alzheimer’s disease--insights from HD studies may help 
identify potential biomarkers for use in these disorders. In addition, the close relationship 
between neuronal cell death and functional disability makes correlation of neuroimaging 
markers with neuropathology and clinical features feasible. Striatal atrophy seems to be a 
remarkably stable and useful biomarker over essentially the entire course of the disease, with 
atrophy beginning 15 years before diagnosable onset and progressive atrophy continuing 
throughout the manifest period. As in Alzheimer disease, and possibly also in Parkinson 
disease, the changes of HD begin very early in the disease course.127 Therefore, treatment can 
have the goal of delaying or preventing clinical onset, as well as slowing progression of 
established disease. Biomarkers are likely to be most relevant for clinical trials in these early 
presymptomatic and prodromal periods.127 
Different biomarkers might be more useful at different points in the course of HD. Steady 
progression of atrophy is observed in the striatum and other brain regions, and has the potential 
for utility over long periods. Cortical grey matter and hippocampal volumes might be more useful 
markers later in the disease course, especially when correlated with cognitive variables. 
A number of questions remain to be answered. For example, which functional and 
chemical measures will be most useful and most responsive to therapeutic interventions? Do 
neurobiological features accelerate, resulting in biomarker changes, just prior to onset of HD? 
Also, which biomarkers correlate best with which clinical features of the disease at each stage in 
the longitudinal course?  A general biological question is whether biomarkers can be expected 
to correlate with CAG repeat length in the HD range only, or whether the CAG repeat length 
even within the normal range (Seong et al 2005) is relevant.   
A major—and potentially therapeutically important—question is whether imaging 
biomarkers can be used to trace out circuits and determine the role of cell–cell interactions 
(Figure 6). The combination of several MRI methods may be especially powerful.  For instance it 
may be possible to use tract-tracing DTI and fMRI function connectivity (or PET correlation 
analysis) to trace changes in pathways between subregions of brain structures defined as 
atrophic  by shape analysis.  This analysis may guide therapeutics.  In one scenario, if HD 
neuronal degeneration begins in the striatum and then progresses to other brain regions, it is 
conceivable that injection of RNA interference reagents into the striatum very early in the course 
might be sufficient to interrupt pathogenesis. Conversely, if HD pathogenesis begins in the 
cortex and progresses via anterograde mechanisms to the striatum, then superfusion of 
antisense oligonucleotides over the cortex might be sufficient to interrupt pathogenesis. If the 
pathology is largely cell-autonomous and occurs simultaneously in cortex and striatum, 
however, then severalinterventions together would be indicated. Of course, highly brain-
penetrant small molecules are likely to be effective no matter which of these mechanisms is 
most relevant. 
In summary, the validation of biomarkers for future trials of disease-modifying 
therapeutics to delay the onset and slow the progression of HD seems increasingly feasible. 
These biomarkers could be useful as outcome measures in phase II studies, and in the future 
might even be developed as surrogate markers for phase III studies. In turn, the methods 
developed for HD may be useful for development of personalized preventive therapeutics for 
other neurodegenerative diseases. 
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Figure 1 | Natural history of clinical HD, and hypothesized changes in selected imaging 
biomarkers. The x-axis is the CAP score (Box 2), which enables the progression of many 
individuals with different CAG expansion lengths to be plotted on the same graph. [Because of 
“normalization,”  mean disease onset is at a CAP score of around 100, but there is substantial 
inter-individual variability, part of which is due to genetic modifiers, which are currently being 
sought a | Natural history. The period before the appearance of diagnosable signs and 
symptoms of HD is termed ‘premanifest’ to distinguish from the period after ‘manifest’ signs and 
symptoms are present. However, subtle signs and symptoms are usually present well before the 
presence of manifest HD. This period is, therefore, termed ‘prodromal’ HD. The period during 
which no signs or symptoms of HD are present is termed ‘presymptomatic’. The period of 
manifest HD is characterized by slow progression of motor and cognitive difficulties, with chorea 
often prominent early but plateauing or even decreasing later, while  fine motor impairment 
(incoordination bradykinesia and rigidity) progress more steadily. b | Hypothetical trajectory of 
several imaging biomarkers.  The values on the Y-axis refer to brai region volumes as a 
percentage of baseline volumesThis is an approximation, since the PREDICT-HD and TRACK-
HD studies have not followed individuals across the entire range of premanifest and manifest 
HD. Abbreviations: CAP, CAG–age product; HD, Huntington disease. 
 
Figure 2 | Longitudinal data from TRACK-HD. Examples of the most robust changes in 
premanifest and early HD identified by the TRACK-HD study over 36 months of longitudinal 
study.12 a,b | Rates of striatal atrophy. Change in white matter volume, seen as statistical 
parametric maps and presented as atrophy rates by group. c | Tapping test to quantify motor 
function. d | Symbol Digit Modalities Test to assess visual attention and psychomotor speed. e,f 
| UHDRS scores total motor and functional capacity respectively. Abbreviations: HD, Huntington 
disease. UHDRS, Unified HD Rating Scale. PreHD-A refers to premanifest far from onset, and 
PreHD-B refers to premanifest close to onset.  HD1 refers to early HD, HD2 later stage HD The 
asterisks refer to levels of significance, and the dasked lines indicate specific comparisons  
 
Figure 3 | Change with CAP score of clinical and imaging variables from TRACK-HD. a,b | 
Striatal volumes. c | Tapping test to quantify motor function. d | Symbol Digit Modalities Test to 
assess visual attention and psychomotor speed. e,f | UHDRS scoresA colour key differentiates 
longitudinal changes in participants with clinical HD, preHD and observed conversion from 
premanifest HD (preHD) to HD (‘converters’ ) Note the very steady change in striatal volumes in 
all patient groups  Abbreviations: CAP, CAG–age product; HD, Huntington disease. UHDRS, 
Unified HD Rating Scale. 
  
 
Figure 4 | Change in clinical features: data from the COHORT and REGISTRY databases. 
Clinical features (TMS, Chorea Score, TFC and Symbol Digit Modalities Test) are plotted 
against CAP scores for gene-positive individuals (HD) and against age for healthy controls. 
Data for patients with HD are age-adjusted (that is, expected values for healthy controls of 
comparable ages are subtracted from all data points). Trend lines are based on a mixed effects 
nonlinear model that is under development by the Model-HD project. Diagnostic status and 
Shoulson–Fahn stages are shown by colour coding. To improve the readability of the graphs, 
only baseline values for patients with HD are shown. The modelling data set excludes healthy 
controls with fewer than two visits, and HD patients with fewer than three visits or CAP scores 
>160. Considerable variability in clinical features is seen in both patients and controls, and the 
slopes of the trend lines increase around the time of expected HD diagnosis in patients with HD 
(CAP score about 100). The flattening of trend lines for CAP scores >120 might be attributable 
to under-representation of the sickest patients in this region. Abbreviations: CAP, CAG–age 
product; HD, Huntington disease; TFC, Total Functional Capacity; TMS, Total Motor Score. 
 
Figure 5 | Schematic diagram of Huntington disease cellular pathogenesis, highlighting 
pathways with potential for biomarker development (red-rimmed boxes)]. In some cases, the 
molecule might be involved directly in pathogenesis, as with huntingtin itself, and might, 
therefore, also be a therapeutic target and serve as a pharmacodynamics marker as well as a 
marker of disease status. Abbreviations: Ac, acetyl group, P phosphate group and Su SUMO  
post-translational modifications  BDNF, brain-derived neurotrophic factor; ROS, reactive oxygen 
species. 
 
Figure 6 | Conceptual diagram of possible circuitry-related degeneration in Huntington 
disease. The hypothesis is that pathogenesis spreads via some form of intercellular 
communication, which could involve transmission of mutant huntingtin from cell to cell in a 
prion-like fashion. Excitotoxicity and/or loss of trophic support could also be involved in 
pathogenesis involving cell-cell interactions.   If imaging measures can be used to track the 
initiation and spread of such a process, it may be possible to target huntingtin-lowering 
interventions to the initiating regions of the brain at the optimal time in order to minimize 
spread.  
  
Box 1 | Biomarker definitions 
 
Biological marker (biomarker) 
A characteristic that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacological responses to a therapeutic intervention. 
 
Clinical end point 
A characteristic or variable that reflects how a patient feels or functions, or how long a patient 
survives. 
 
Surrogate end point 
A biomarker intended to substitute for a clinical end point. A clinical investigator can use 
epidemiological, therapeutic, pathophysiological or other scientific evidence to select a 
surrogate end point that is expected to predict clinical benefit or harm, or lack thereof. 
 
Criteria for biomarkers 
Can be objectively measured 
Predicts clinically meaningful end points 
Associated with known disease mechanisms and pathology 
Predicts response to treatment 
Associated with biologically relevant response to treatment 
 
It is important to evaluate biomarkers critically in the context of the disease mechanism. For 
instance, some have speculated that striatal volumes could be artefactually increased by 
oedema or inflammation, or even conceivably by administration of large quantities of 
substances that add bulk to cytoplasm or cell membranes. In these instances, changes in 
striatal volumes would not reflect disease status, and such measurements could give unreliable 
or incorrect information about the disease and potential treatments.
  
Box 2 | CAP score and HD progression 
As used in this Review, the CAP score is defined follows: CAP = 100 × AGE × [(CAG–L) ÷ S],  
where CAG is the patient’s CAG repeat length, AGE is the patient’s current age at the time of 
observation, and L and S are constants. S is a normalizing constant chosen so that the CAP 
score is approximately 100 at the patient’s expected age of onset as estimated by Langbehn et 
al. (2004).128 L is a scaling constant that anchors CAG length approximately at the lower end of 
the distribution relevant to HD pathology. L has been estimated at slightly different values; for 
example, Zhang et al. use L = 33.66,20 whereas Penney et al. use L = 35.5.19 
 The graphs shown in this Review use L = 30 and S = 627, which are estimates obtained 
by a reanalysis of the data in Langbehn et al.128 presented by Warner and Hayden.129 In this 
respect, it is similar to measures from Langbehn et al.128 related to onset risk. The optimal value 
of L was also found to be about 30 for correlation with a wide variety of clinical measures as 
reported by Langbehn et al.130 Intuitively, L might be thought of as the lower limit of the CAG 
lengths for which some pathological effect might be expected. Direct evidence for detectable HD 
pathology in the CAG range 30–35 is sparse and controversial, so the exact value of L within 
this range might be difficult to interpret. Nevertheless, the existence of a striking threshold for 
pathogenesis is reflected in the equation. 
 Abbreviations: CAP, CAG–age product;; HD, Huntington disease. 
